HENGRUI PHARMA - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

or completeness of this announcement, and expressly expressly disclaims any liability arising out of or in reliance upon the whole or any part of the contents of this announcement. assumes no responsibility for any losses caused by such content.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Jiangsu Hengrui Pharmaceutical Co., Ltd.

(a joint stock limited company incorporated in the People's Republic of China) (Stock code: 1276)

Overseas regulatory announcement

This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

In accordance with the relevant laws and regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceutical Co., Ltd. (the "Company")

The Shanghai Stock Exchange website (www.sse.com.cn) published the following announcement. They are listed below for reference only.

By order of the board of directors Jiangsu Hengrui Pharmaceutical Co., Ltd. Chairman

Mr. Sun Piaoyang

Shanghai, China March 25, 2026

As at the date of this announcement, members of the Board of Directors include (i) Executive Directors Mr. Sun Piaoyang, Mr. Dai Hongbin, and Mr. Feng Jinu; Mr. Zhang Lianshan, Mr. Jiang Ningjun and Mr. Sun Jieping; (ii) Ms. Guo Congzhao, a non-executive director; and (iii)

Independent non-executive directors are Mr. Dong Jiahong, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Zhou Ji'en.

Securities code: 600276 Securities abbreviation: Hengrui Medicine Announcement number: Lin 2026-048

Jiangsu Hengrui Pharmaceutical Co., Ltd.

2025 annual profit distribution plan and submission to the shareholders’ meeting for authorization to the board of directors

Announcement on formulating the mid-term dividend plan for 2026

The board of directors and all directors of the company guarantee that the contents of this announcement do not contain any false records or misleading statements. or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its content.

Important content tips:

 Distribution ratio per share: Cash dividend of 0.2 yuan per share (tax included).

 The share capital of this profit distribution shall be based on the share capital on the registration date of dividend payment (excluding the company’s special securities for share repurchase). The number of shares held in the account) is the base number, and the specific date will be clarified in the equity distribution implementation announcement. 

 If the company’s total share capital changes before the equity registration date for equity distribution, it is planned to maintain the dividend per share

The allocation ratio remains unchanged, the total allocation will be adjusted accordingly, and the specific adjustments will be announced separately.

 The company’s board of directors proposes to the shareholders’ meeting to authorize the board of directors to make profit distribution in accordance with the resolution of the shareholders’ meeting.

Other specific mid-term dividend plans for 2026 will be formulated under the conditions.  A brief explanation of the reasons why the cash dividend ratio this year is lower than 30%: First, the company is in an industry

Pharmaceutical industry, the pharmaceutical industry has the characteristics of high investment, high risk, long development cycle and high cost of innovative drugs.

In particular, the company is currently in a critical stage of transformation from generic drugs to innovative drugs and requires a large amount of capital investment at home and abroad.

Clinical trials and innovative drug research and development; secondly, the company is currently conducting factory trials in Guangdong, Beijing, Tianjin and other places

New expansion requires a large investment; thirdly, the company plans to increase cooperation with international R&D institutions to store Prepare more innovative drug varieties to enhance global competitiveness, and relevant cooperation projects require higher financial support.



1. Profit distribution plan for 2025

(1) Contents of the 2025 profit distribution plan

As audited by Ernst & Young Hua Ming LLP (Special General Partnership), the company achieved vesting in 2025 The net profit of the owners of the parent company is 7,711,054,811.98 yuan, and the consolidated undistributed profit at the end of the period is

40,173,354,828.03 yuan, and the undistributed profit of the parent company at the end of the period was 34,876,729,292.92 yuan.

The profit distributed to shareholders is 34,876,729,292.92 yuan. According to the resolution of the board of directors, the company plans to use

The share capital on the record date of dividend payment (excluding the number of shares held in the company’s special securities account for share repurchase) is the base for dividend distribution. Run. The profit distribution plan is as follows:

The listed company plans to distribute a cash dividend of 2 yuan (tax included) to all shareholders for every 10 shares. By 2026 3

On March 16, the company’s total share capital was 6,637,199,874 shares, of which the special account for repurchasing shares held the company’s shares.

6,787,650 shares. According to regulations, these shares will not participate in this profit distribution. Based on this, the total cash to be distributed is calculated.

Dividends are RMB 1,326,082,444.80 (tax included). The actual amount of cash dividends distributed will be based on the equity registration date. The number of shares held by the company's repurchase account on that day will be adjusted accordingly.

According to Article 8 of the "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 7 - Repurchase of Shares"

Regulations: "If a listed company uses cash as consideration and adopts centralized bidding or tender offer to repurchase shares,

The amount of share repurchases implemented during the year is regarded as cash dividends and is included in the calculation of the relevant proportion of cash dividends for that year.

Forget it. "In 2025, the company's cumulative share repurchase amount is 978,094,542.12 yuan. After adding this amount, it is now The total amount of gold dividends is 2,304,176,986.92 yuan, accounting for the company’s net profit attributable to shareholders of listed companies in 2025.

29.88% of profits. Among them, cash is used as consideration, and shares are repurchased through tender offer and centralized bidding.

The amount of canceled repurchases (hereinafter referred to as repurchases and cancellations) is 0 yuan, and the total amount of cash dividends and repurchases and cancellations is

1,326,082,444.80 yuan, accounting for 17.20% of the net profit attributable to shareholders of the listed company this year.

If the company's total share capital changes between the date of disclosure of this announcement and the equity registration date for equity distribution, The company plans to maintain the distribution ratio per share unchanged and adjust the total distribution accordingly. If the total share capital subsequently changes,

Specific adjustments will be announced separately.

This profit distribution plan still needs to be submitted to the shareholders' meeting for review.

(2) Whether other risk warning situations may be involved

The company’s cumulative dividend payment in the last three fiscal years is RMB 3,873,980,958.40; The amount of cash dividends accounts for 63.33% of the average annual net profit in the past three fiscal years. The above indicators do not touch the "stock

Other risk warnings may be imposed as specified in Item (8) of Article 9.8.1 of Article 9.8.1 of the Stock Exchange Listing Rules.

shape, the specific indicators are as follows:

Item Current year Previous year Previous year Total cash dividends (yuan) 1,326,082,444.80 1,274,130,192.80 1,273,768,320.80

Total amount of repurchase and cancellation (yuan) — — — Net attributable to shareholders of listed companies 7,711,054,811.98 6,336,527,014.75 4,302,435,930.05 Profit (yuan)

The parent company's financial statements at the end of the year are not divided into 34,876,729,292.92 Distribution profit (yuan) Cumulative cash for the past three fiscal years 3,873,980,958.40 Total amount of gold dividends (yuan) The cumulative returns for the past three fiscal years have been — Total purchase and cancellation amount (yuan) The average net income of the last three fiscal years 6,116,672,585.59 Profit (yuan) Cumulative cash for the past three fiscal years 3,873,980,958.40 Total amount of gold dividends and repurchase cancellation (yuan) Cumulative cash for the past three fiscal years Is the total amount of gold dividends and buyback write-off low? No At NT$50 million Cash dividend ratio (%) 63.33 Is the cash dividend ratio lower than No 30% Whether it touches the Stock Listing Rules Article 9.8.1 Paragraph 1 (8) No Certain other risk warnings may be implemented situation (3) Explanation of the situation where the cash dividend ratio for the year is less than 30% During the reporting period, the company’s net profit attributable to ordinary shareholders of the listed company was RMB 7,711,054,811.98. The total cash dividends planned to be distributed by the listed company is 2,304,176,986.92 yuan, accounting for 10% of the total cash dividends attributed to the listed company this year. The net profit ratio of the company’s shareholders is less than 30%. The board of directors’ explanation of this profit distribution plan is as follows:

First, the company is in the pharmaceutical industry, which is characterized by high investment, high risk, and innovative drug research and development. The development cycle is long and the cost is high, especially since the company is currently at the critical stage of transforming from generic drugs to innovative drugs.

stage, a large amount of capital is needed to invest in clinical trials and innovative drug research and development at home and abroad; secondly, the company is currently conducting research and development in Guangdong,

New expansion of factory areas in Beijing, Tianjin and other places requires a large investment; thirdly, the company plans to expand

Cooperate with international R&D institutions to reserve more innovative drug varieties to enhance global competitiveness and related cooperation projects

Requires higher financial support. 2. Request the shareholders’ meeting to authorize the board of directors to formulate an interim dividend plan for 2026

In order to maintain a stable frequency of dividend distribution and enhance the level of returns for investors, based on the actual situation of the company, the directors of the company

The board of directors proposed to the shareholders' meeting to review and approve the conditions and upper limit of the 2026 interim cash dividend, and authorized the board of directors to

According to the resolution of the shareholders' meeting, a specific mid-term dividend plan for 2026 will be formulated subject to the conditions for profit distribution.

1. Prerequisites for mid-term dividends (1) Profitable during the reporting period and the undistributed profits in the parent company’s statements are positive;

(2) The company’s cash flow can meet the needs of normal operations and sustainable development;

(3) Comply with the "Supervisory Guidelines for Listed Companies No. 3 - Cash Dividends of Listed Companies" and "Shanghai Securities

"Rules Governing the Listing of Securities on the Exchange", "Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited", "Corporate Articles" "Process" and other relevant regulations on the profit distribution requirements of listed companies.

2. The upper limit of the amount of interim dividends shall not exceed the net profit attributable to the company’s shareholders during the corresponding period.

3. Decision-making procedures implemented by the company

The company held the 24th meeting of the ninth board of directors on March 25, 2026, with 11 votes in favor and 0 votes against.

Yes, the voting results of 0 abstentions reviewed and approved the "Company's 2025 Profit Distribution Plan and Submission to the Shareholders' Meeting" Proposal to Authorize the Board of Directors to Formulate an Interim Dividend Plan for 2026" and agreed to the profit distribution plan.

The profit distribution plan still needs to be submitted to the company's 2025 annual shareholders' meeting for review.

4. Related risk warnings

This profit distribution plan combines the company’s development stage, future capital needs and other factors, and will not be detrimental to the company.

It will have a significant impact on the company's operating cash flow and will not affect the company's normal operations and long-term development. This profit distribution The plan still needs to be submitted to the company's shareholders' meeting for review and approval before it can be implemented. Investors are advised to pay attention to guard against investment risks.

Risk.

Announcement is hereby made.

Board of Directors of Jiangsu Hengrui Pharmaceutical Co., Ltd.

March 25, 2026